Monopar Therapeutics Inc (MNPR)

$81.57 +0.28 (0.34%)
Market Cap 501.56M
Revenue (ttm) 0.00
Net Income (ttm) -15.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 51,700
Avg Vol 65,034
Day's Range N/A - N/A
Shares Out 6.17M
Stochastic %K 30%
Beta 1.42
Analysts Strong Sell
Price Target $109.91

Company Profile

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imagi...

Industry: Biotechnology
Sector: Healthcare
Phone: 847 388 0349
Address:
1000 Skokie Boulevard, Suite 350, Wilmette, United States
TA_Kongen
TA_Kongen Oct. 23 at 8:05 PM
$MNPR WTF. Last time I traded this was at like 5. What happened lmao.
1 · Reply
Dbi2
Dbi2 Oct. 21 at 7:09 PM
$MNPR what's going on?
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 20 at 3:51 PM
Lantheus loading up on $RADX $CATX $RANI $MNPR
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 19 at 12:53 AM
$RADX Another major investment into Radiopharm Theranostics by Lantheus being announced on Monday. $ATNM $CLRB $MNPR $CLRB
3 · Reply
MikeZ28
MikeZ28 Oct. 14 at 9:26 PM
$CABA 1000 shares deep in this one. Nice bounce back from last week. Hoping for a $NVAX or $MNPR type of run here over the next several weeks. Looking for a $15-20 price target.
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 14 at 5:10 PM
$56.4 million market cap is tiny in radiopharmaceutical’s… DEEP PIPELINE imaging & therapeutics $LNTH paying $250-300 mil per acquisition They just invested at $11.85 in Q1. Trading $4.75 below their last investment to bring ownership up to 12% PD-L1 and Her2 potential blockbusters $4-10 billion annually combined.. Rad101 high % success on Brain metastasis imaging batting 1000% in phase2a/b so far as I know- $400-800 mil annual imaging agent… $RADX $NNE $MNPR $MP
2 · Reply
Paraboljoker
Paraboljoker Oct. 14 at 8:02 AM
$XCH Next lithium to go like !$SPRB $DRUG $MNPR $AQMS
0 · Reply
Paraboljoker
Paraboljoker Oct. 14 at 12:03 AM
$XCH Undervalued🤌🏼💎 Has that returns of $SPRB $DRUG $MNPR $AQMS written all-over her💥 https://finance.yahoo.com/news/xcharge-north-america-ascentium-capital-113000948.html
0 · Reply
Paraboljoker
Paraboljoker Oct. 13 at 7:27 PM
$SUGP $SPRB $STI $MNPR $DRUG SUGP Matrix squeeze candidate☝🏼🌋
1 · Reply
Paraboljoker
Paraboljoker Oct. 13 at 7:11 PM
$SUGP 400K Float 🗞️ 1More PR and holymoly🇭🇰👀 Supply of shares will be shocked🔥 Could be new $SPRB $STI $MNPR $DRUG if u ask me
0 · Reply
Latest News on MNPR
Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025

Oct 15, 2025, 8:00 AM EDT - 10 days ago

Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025

Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Sep 23, 2025, 11:08 PM EDT - 4 weeks ago

Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Monopar Announces Journal of Hepatology Publishes Physicians' Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients

Sep 23, 2025, 11:07 PM EDT - 4 weeks ago

Monopar Announces Journal of Hepatology Publishes Physicians' Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients

Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting

Sep 14, 2025, 8:00 AM EDT - 5 weeks ago

Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting

Monopar Therapeutics: A Speculative Buy On 2 Fronts With Catalysts Imminent

Sep 4, 2025, 10:29 AM EDT - 7 weeks ago

Monopar Therapeutics: A Speculative Buy On 2 Fronts With Catalysts Imminent

Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting

Sep 3, 2025, 8:00 AM EDT - 7 weeks ago

Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting

Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments

Aug 12, 2025, 8:00 AM EDT - 2 months ago

Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments

Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

Jun 11, 2025, 7:00 AM EDT - 4 months ago

Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Jun 3, 2025, 7:00 AM EDT - 5 months ago

Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

May 13, 2025, 8:00 AM EDT - 5 months ago

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

May 7, 2025, 2:30 AM EDT - 6 months ago

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025

Apr 29, 2025, 8:00 AM EDT - 6 months ago

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025

Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments

Mar 31, 2025, 8:00 AM EDT - 7 months ago

Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments

Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics

Jan 23, 2025, 1:10 PM EST - 9 months ago

Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics

Monopar: Radiopharmaceutical Company With 2 Radioisotope Development Pathways

Dec 23, 2024, 2:23 PM EST - 10 months ago

Monopar: Radiopharmaceutical Company With 2 Radioisotope Development Pathways

Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

Dec 20, 2024, 9:00 AM EST - 11 months ago

Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu

Dec 5, 2024, 4:21 PM EST - 11 months ago

Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu

Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference

Dec 3, 2024, 8:00 AM EST - 11 months ago

Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference

Monopar Therapeutics: Radiopharmaceuticals And Rare Disease Potential In Focus

Nov 25, 2024, 7:53 PM EST - 11 months ago

Monopar Therapeutics: Radiopharmaceuticals And Rare Disease Potential In Focus

Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments

Nov 8, 2024, 8:00 AM EST - 1 year ago

Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments

Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock

Oct 30, 2024, 1:42 PM EDT - 1 year ago

Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock

Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock

Oct 28, 2024, 9:15 PM EDT - 1 year ago

Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock

Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock

Oct 28, 2024, 4:00 PM EDT - 1 year ago

Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock

Up 600% Then Down 50% In 2 Days: What Is Going On With MNPR Stock?

Oct 28, 2024, 1:29 PM EDT - 1 year ago

Up 600% Then Down 50% In 2 Days: What Is Going On With MNPR Stock?

Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder

Oct 24, 2024, 1:18 PM EDT - 1 year ago

Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder

AZN

Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024

Oct 22, 2024, 8:00 AM EDT - 1 year ago

Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024

Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers

Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr

Sep 12, 2024, 8:00 AM EDT - 1 year ago

Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr

Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule

Aug 27, 2024, 4:05 PM EDT - 1 year ago

Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule

Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers

Aug 21, 2024, 8:00 AM EDT - 1 year ago

Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers

Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr

Aug 14, 2024, 8:00 AM EDT - 1 year ago

Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr

Monopar Therapeutics Announces 1-for-5 Reverse Stock Split

Aug 9, 2024, 8:00 AM EDT - 1 year ago

Monopar Therapeutics Announces 1-for-5 Reverse Stock Split

Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments

Aug 9, 2024, 8:00 AM EDT - 1 year ago

Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments

Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM'24

Jun 25, 2024, 8:00 AM EDT - 1 year ago

Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM'24

Monopar and NorthStar Amend & Extend Collaboration

Jun 11, 2024, 7:30 AM EDT - 1 year ago

Monopar and NorthStar Amend & Extend Collaboration

Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting

Jun 10, 2024, 8:00 AM EDT - 1 year ago

Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting

Monopar Announces CFO Succession

May 24, 2024, 8:00 AM EDT - 1 year ago

Monopar Announces CFO Succession

Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline

May 9, 2024, 7:00 AM EDT - 1 year ago

Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline

Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting

Apr 18, 2024, 8:00 AM EDT - 1 year ago

Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting

Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients

Apr 10, 2024, 8:00 AM EDT - 1 year ago

Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients

Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments

Mar 28, 2024, 7:00 AM EDT - 1 year ago

Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments

Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program

Mar 5, 2024, 7:00 AM EST - 1 year ago

Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program

Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial

Feb 27, 2024, 7:00 AM EST - 1 year ago

Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial

Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers

Feb 20, 2024, 8:00 AM EST - 1 year ago

Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers

Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments

Nov 9, 2023, 7:00 AM EST - 2 years ago

Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments

Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

Nov 1, 2023, 7:00 AM EDT - 2 years ago

Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference

Oct 10, 2023, 7:00 AM EDT - 2 years ago

Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference

Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments

Monopar to Participate in the Radiopharma Forum by the Lake 2023

Jun 21, 2023, 7:00 AM EDT - 2 years ago

Monopar to Participate in the Radiopharma Forum by the Lake 2023

Monopar to Participate in the Maxim Group's Healthcare Virtual Conference

Jun 14, 2023, 7:00 AM EDT - 2 years ago

Monopar to Participate in the Maxim Group's Healthcare Virtual Conference

TA_Kongen
TA_Kongen Oct. 23 at 8:05 PM
$MNPR WTF. Last time I traded this was at like 5. What happened lmao.
1 · Reply
Dbi2
Dbi2 Oct. 21 at 7:09 PM
$MNPR what's going on?
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 20 at 3:51 PM
Lantheus loading up on $RADX $CATX $RANI $MNPR
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 19 at 12:53 AM
$RADX Another major investment into Radiopharm Theranostics by Lantheus being announced on Monday. $ATNM $CLRB $MNPR $CLRB
3 · Reply
MikeZ28
MikeZ28 Oct. 14 at 9:26 PM
$CABA 1000 shares deep in this one. Nice bounce back from last week. Hoping for a $NVAX or $MNPR type of run here over the next several weeks. Looking for a $15-20 price target.
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 14 at 5:10 PM
$56.4 million market cap is tiny in radiopharmaceutical’s… DEEP PIPELINE imaging & therapeutics $LNTH paying $250-300 mil per acquisition They just invested at $11.85 in Q1. Trading $4.75 below their last investment to bring ownership up to 12% PD-L1 and Her2 potential blockbusters $4-10 billion annually combined.. Rad101 high % success on Brain metastasis imaging batting 1000% in phase2a/b so far as I know- $400-800 mil annual imaging agent… $RADX $NNE $MNPR $MP
2 · Reply
Paraboljoker
Paraboljoker Oct. 14 at 8:02 AM
$XCH Next lithium to go like !$SPRB $DRUG $MNPR $AQMS
0 · Reply
Paraboljoker
Paraboljoker Oct. 14 at 12:03 AM
$XCH Undervalued🤌🏼💎 Has that returns of $SPRB $DRUG $MNPR $AQMS written all-over her💥 https://finance.yahoo.com/news/xcharge-north-america-ascentium-capital-113000948.html
0 · Reply
Paraboljoker
Paraboljoker Oct. 13 at 7:27 PM
$SUGP $SPRB $STI $MNPR $DRUG SUGP Matrix squeeze candidate☝🏼🌋
1 · Reply
Paraboljoker
Paraboljoker Oct. 13 at 7:11 PM
$SUGP 400K Float 🗞️ 1More PR and holymoly🇭🇰👀 Supply of shares will be shocked🔥 Could be new $SPRB $STI $MNPR $DRUG if u ask me
0 · Reply
JarvisFlow
JarvisFlow Oct. 13 at 12:05 PM
Barclays has adjusted their stance on Monopar Therapeutics ( $MNPR ), setting the rating to Overweight with a target price of 125.
0 · Reply
notreload_ai
notreload_ai Oct. 13 at 10:06 AM
Barclays assigns Overweight rating to $MNPR with $125 price target, highlighting de-risked biotech opportunities in inflammation, rare disease, and oncology sectors. https://notreload.xyz/barclays-initiates-monopar-therapeutics-bullish-coverage/
0 · Reply
georgenobest
georgenobest Oct. 11 at 6:43 PM
$MNPR CATX more than 300% upside. Catalyst coming next week. The move just started https://in.investing.com/news/analyst-ratings/btig-initiates-coverage-on-perspective-therapeutics-stock-with-buy-rating-93CH-5038968
0 · Reply
DrevanTheStillblade
DrevanTheStillblade Oct. 7 at 11:14 AM
PRHI is suffocating the shorts. Borrow’s gone. Utilization near max. Short squeeze score nearly perfect. One green candle with volume and they scramble. $4.05 break = liftoff. $7–$10 range is real.... . $AMST $ACHV $BLPH $VYNE $MNPR
0 · Reply
DARKP00L
DARKP00L Oct. 6 at 5:11 PM
$MNPR 12:59 on Oct. 06 2025 Raymond James Maintains Strong Buy on Monopar Therapeutics, Raises Price Target to $142 #tradeideas
0 · Reply
ya33
ya33 Oct. 6 at 5:09 PM
$MNPR
0 · Reply
JarvisFlow
JarvisFlow Oct. 6 at 4:59 PM
Raymond James has adjusted their stance on Monopar Therapeutics ( $MNPR ), setting the rating to Strong Buy with a target price of 80 → 142.
0 · Reply
FloatExplorer
FloatExplorer Oct. 5 at 12:14 PM
$MNPR Biotech with novel approach. High short interest. Potential squeeze setup if data positive. High risk/reward.
0 · Reply
Bullbear1010101
Bullbear1010101 Oct. 4 at 12:33 PM
$MNPR Seems top soon. bubble almost
0 · Reply
StockTwitsGhost
StockTwitsGhost Oct. 3 at 9:58 PM
$MNPR If MNPR csn do it, so can $CYCN 💪🏽
0 · Reply
TradeHuntFish
TradeHuntFish Oct. 3 at 1:06 PM
If GIPR becomes the next REIT-crypto hybrid play, the re rate will be violent. Add in a micro float, real tenants, and a book value that’s completely ignored this could be the next legendary rerate ticker. Eyes on this before it headlines. $MNPR $THMO $LGVN $HOOK $PEV
0 · Reply
outlawinvestor1
outlawinvestor1 Oct. 2 at 2:37 PM
$RADX $MNPR and $RADX are completely different companies with different value drivers. one is not an indicator of what the other can do. they're both good opportunities imho, but no need to compare.
3 · Reply